Nuwellis, Inc.NUWE

Nuwellis, Inc. is a medical device company focused on ultrafiltration systems for fluid overload management, selling into heart failure, critical care, and paediatric markets. Its product rail promises precise fluid removal tailored to complex patient needs, positioning the company as a niche player in a space dominated by dialysis giants. The company’s website and investor materials frame it as an innovator investing in the future of medical fluid management technology, but the filings tell a less futuristic tale. In the quarter to 31 March 2026, Nuwellis booked $2.4 million in revenue while posting a net loss of $4.5 million, or $2.19 per diluted share, on just 2.1 million weighted average shares outstanding. Operating loss was $4.6 million, operating cash flow was negative $3.1 million, and the company held $2.1 million in cash with $4.3 million in liabilities against $7.0 million in assets. Shareholder equity stood at a slender $2.7 million, a figure that feels less like a balance-sheet pillar and more like a balance-beam act. (source: Nuwellis 10-Q (period ending 2026-03-31), https://www.sec.gov/Archives/edgar/data/1506492/000114036126019366/0001140361-26-019366-index.htm)

Nuwellis’s ultrafiltration devices are designed to remove excess fluid in conditions like acute decompensated heart failure and critical illness, where traditional diuretics may fail or cause harm. The company’s clinical solutions page highlights heart failure, critical care, and paediatrics, and the investor rail frames the technology as precise and tailored. Yet the numbers show the business is still in the early innings of commercial scale. Research and development expense was $1.7 million in the quarter, roughly 70% of revenue, while capital expenditure was just $30,000, suggesting the company is prioritising burn over build. Inventory sat at $1.8 million, down $181,000 in the quarter, a modest reduction that does little to signal robust demand or supply-chain mastery. (source: Nuwellis 10-Q (period ending 2026-03-31), https://www.sec.gov/Archives/edgar/data/1506492/000114036126019366/0001140361-26-019366-index.htm; Nuwellis Clinical Solutions for Fluid Overload, https://nuwellis.com/solutions/)

The company’s filings reveal a board trying to keep the lights on. The DEF 14A for the 2026 annual meeting is a governance document dressed in its Sunday best, but it also confirms that Nuwellis triggered Nasdaq Listing Rule 5635(d) and needs stockholder approval for a reverse stock split to maintain its listing. The PRE 14A filing explicitly states that Rule 5635(d) requires stockholder approval of the transaction, and the proxy statement is hosted at https://web.viewproxy.com/nuwe/2026sm. The company’s June 2026 8-K announcing the appointment of John L. McCormick as a consultant-turned-CCO arrives with corporate polish, but the real story is that Nuwellis is still haemorrhaging cash and needs structural help just to stay listed. (source: Nuwellis DEF 14A (2026-07-07), https://www.sec.gov/Archives/edgar/data/1506492/000153949726001914/n5983_x2-def14a.htm; Nuwellis PRE 14A (2026-06-26), https://www.sec.gov/Archives/edgar/data/1506492/000153949726001874/n5983_x1-sch14a.htm; Nuwellis 8-K (2026-06-18), https://www.sec.gov/Archives/edgar/data/1506492/000114036126025614/ef20076374_8k.htm)

For context on the operating mechanics and market mechanism, the company’s investor page aggregates financial reports, SEC filings, and stock performance data, while its SEC company facts JSON provides structured XBRL data for machine readers. The JSON filing index confirms the breadth of disclosures but does not change the underlying arithmetic. The company’s Nasdaq listing, shareholder equity, and cash position remain the binding constraints, not the rhetoric on the website. (source: Nuwellis Investor Relations, https://www.nuwellis.com/investors/; Nuwellis SEC filings index, https://www.sec.gov/edgar/browse/?CIK=1506492; Nuwellis SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001506492.json)

What changed this quarter is the continued cash burn, the modest inventory drawdown, and the board’s admission that it needs a reverse stock split to stay listed. What remains unproven is whether Nuwellis can scale ultrafiltration into a commercially viable business without accelerating dilution or raising fresh capital. The evidence suggests the company is still in the burn phase, with R&D running at 70% of revenue and capital expenditure near zero. The next evidence that would deepen the file would be a quarter where revenue exceeds $3 million while net loss narrows below $3 million, or a filing that discloses a strategic transaction or capital raise. Until then, the balance sheet is the message, and the message is thin. (source: Nuwellis 10-Q (period ending 2026-03-31), https://www.sec.gov/Archives/edgar/data/1506492/000114036126019366/0001140361-26-019366-index.htm)